moxifloxacin has been researched along with Soft Tissue Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q | 1 |
| Bosc, R; Chosidow, O; De Prost, N; Hua, C; Hughes, C; Jabre, P; Le Cleach, L; Sbidian, E | 1 |
| Giamarellos-Bourboulis, EJ; Ioannidis, O; Koutelidakis, I; Papaziogas, B; Paraskevas, G; Tsiaousis, P | 1 |
| Joukhadar, C; Kovar, F; Lackner, E; Minar, E; Müller, M; Müller-Zellenberg, U; Stass, H | 1 |
| Citron, DM; Goldstein, EJC; Rybak, MJ; Tyrrell, KL; Warren, YA | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
2 review(s) available for moxifloxacin and Soft Tissue Infections
| Article | Year |
|---|---|
Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2017 |
Interventions for necrotizing soft tissue infections in adults.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; CD28 Antigens; Critical Care; Debridement; Female; Fluoroquinolones; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Moxifloxacin; Randomized Controlled Trials as Topic; Soft Tissue Infections | 2018 |
4 other study(ies) available for moxifloxacin and Soft Tissue Infections
| Article | Year |
|---|---|
Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia.
Topics: Animals; Anti-Bacterial Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Immunocompromised Host; Leukocyte Count; Lipid Peroxidation; Male; Moxifloxacin; Rats; Soft Tissue Infections; Stenotrophomonas maltophilia | 2014 |
Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aza Compounds; Diabetes Complications; Diabetes Mellitus; Female; Fluoroquinolones; Humans; Male; Microdialysis; Middle Aged; Moxifloxacin; Quinolines; Soft Tissue Infections; Tissue Distribution | 2003 |
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Community-Acquired Infections; Cross Infection; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus; Virulence; Virulence Factors | 2008 |
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Skin Diseases, Bacterial; Soft Tissue Infections; Wound Infection | 1997 |